Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant - Scorecard - MDSpire
Advertisement
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
Clinical Scorecard: Comprehensive Evaluation of a Phase II Study on Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Without Transplantation
At a Glance
Category
Detail
Condition
Newly diagnosed multiple myeloma (NDMM)
Key Mechanisms
Quadruplet induction therapy combining anti-CD38 monoclonal antibody (daratumumab), proteasome inhibitor (carfilzomib), immunomodulatory imide drug (lenalidomide), and corticosteroid (dexamethasone)
Target Population
Patients aged 18 or older with NDMM regardless of autologous stem cell transplant (ASCT) eligibility
Care Setting
Outpatient oncology treatment with planned 24 cycles of quadruplet therapy without upfront ASCT
Key Highlights
Quadruplet regimen (Dara-KRd) administered for 24 cycles without upfront ASCT in NDMM patients
Primary endpoint: stringent complete response (sCR) and/or minimal residual disease (MRD) negativity at 10−5 threshold after 8 cycles
MRD assessed by next-generation sequencing and peripheral blood mass spectrometry to evaluate deep response
Guideline-Based Recommendations
Diagnosis
Diagnosis of NDMM confirmed by standard criteria with cytogenetic risk stratification by FISH
MRD testing recommended at multiple time points (end of cycles 8, 12, and 24) using NGS with sensitivity to 10−6
Peripheral blood MRD assessment by mass spectrometry is an exploratory adjunct
Management
Induction therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone for up to 24 cycles without immediate ASCT
Stem cell harvest allowed after 4–6 cycles to permit future ASCT if needed
Maintenance therapy with single-agent lenalidomide recommended after completion of induction
Monitoring & Follow-up
Regular assessment of response including sCR and MRD status at defined intervals
Adverse events graded per NCI CTCAE v4.0 throughout treatment
Progression-free survival and overall survival monitored longitudinally
Risks
Potential toxicities related to quadruplet therapy including hematologic and non-hematologic adverse events
Psychological or geographic factors may affect treatment adherence
Uncertain long-term durability of response without ASCT
Patient & Prescribing Data
42 patients with NDMM enrolled, median age 58 years, 57% with high-risk cytogenetic abnormalities
High rates of deep response observed with 67% achieving complete response or better; median treatment duration 23 cycles; 95% evaluable for primary endpoint
Clinical Best Practices
Consider quadruplet induction with Dara-KRd for NDMM patients regardless of ASCT eligibility
Perform MRD testing by sensitive NGS methods at multiple time points to guide response assessment
Offer stem cell collection early during therapy to preserve future transplant options
Implement lenalidomide maintenance post-induction to sustain remission
Monitor patients closely for adverse events and manage according to established toxicity criteria
by Benjamin A. Derman, Jennifer Cooperrider, Jacalyn Rosenblatt, David E. Avigan, Murtuza Rampurwala, David Barnidge, Ajay Major, Theodore Karrison, Ken Jiang, Aubrianna Ramsland, Tadeusz Kubicki, Andrzej J. Jakubowiak
